Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Reports First Quarter 2018 Financial Results
Successful Leadership Transition in Evolution to a Global Commercial Organization ; MONOVISC and CINGAL Global Revenue Increased 38% Year-over-Year; Initiated Voluntary Recall of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX BEDFORD, Mass. --(BUSINESS WIRE)--May 2, 2018-- Anika Therapeutics, Inc.
View HTML
Toggle Summary Anika to Present at the 2018 Deutsche Bank Health Care Conference on May 8, 2018
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 24, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its President and Chief Executive Officer,
View HTML
Toggle Summary Anika to Issue First-Quarter 2018 Financial Results and Business Highlights on Wednesday, May 2
BEDFORD, Mass. --(BUSINESS WIRE)--Apr. 18, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2018 financial results after the close of the market on Wednesday, May 2, 2018 and to hold a conference call the next day, Thursday, May 3,
View HTML
Toggle Summary Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Scaffold at the 2018 World Congress of the International Cartilage Repair Society
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to showcase HYALOFAST ® , a biodegradable,
View HTML
Toggle Summary Anika to Showcase Commercial and Pipeline Portfolio at 2018 AAOS Annual Meeting
BEDFORD, Mass. , March 06, 2018 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its innovative commercial and
View HTML
Toggle Summary Joseph Darling Named CEO and Director of Anika Therapeutics
Dr. Charles Sherwood to retire after 20 years of innovation and leadership at the Company
View HTML
Toggle Summary Anika Reports Fourth Quarter and Full Year 2017 Financial Results
MONOVISC Global Revenue Increased 21% Year-over-Year for Fourth Quarter of 2017; Total Revenue Increased 10% for Full Year of 2017 BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its
View HTML
Toggle Summary Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference call the next day, Thursday, February 22, 2018
View HTML
Toggle Summary Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. , (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced an agreement with the Institute of Integrative Biology at the
View HTML
Toggle Summary Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis
BEDFORD, Mass. --(BUSINESS WIRE)-- A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc. , (NASDAQ: ANIK), a global, integrated orthopedic medicines
View HTML